Novo Nordisk A/S

Novo Nordisk A/S (NYSE: NVO) is a global healthcare company specializing in diabetes management and treatment. It focuses on the research, development, production, and commercialization of pharmaceutical products. The company operates through two primary business segments: Diabetes and Obesity Care and Biopharmaceuticals.

Key Business Updates

• Solid Financial Performance: Novo Nordisk delivered strong financial results for the first half of FY25, with revenue climbing to DKK 154.9 billion from DKK 133.4 billion in the previous year, marking an 18% increase at constant exchange rates (CER). Operating profit surged 29% at CER to DKK 72.2 billion, supported by improved operational efficiency and higher-margin contributions from the diabetes and obesity care segments.
• Enhanced Profitability and Shareholder Value: Gross profit rose 16% year-on-year to DKK 129.2 billion, while the operating margin improved from 43.3% to 46.6%. Net profit advanced 22% to DKK 55.5 billion, translating to diluted earnings per share of DKK 12.49, compared with DKK 10.17 a year earlier. With a free cash flow of DKK 33.6 billion, Novo Nordisk returned DKK 36.5 billion to shareholders through dividends and share repurchases.
• Strong Momentum in Diabetes and Obesity Care: Revenue from diabetes and obesity care climbed 18% to DKK 145.4 billion, accounting for 95% of total sales. Obesity care was the primary growth catalyst, surging 58% at CER to DKK 38.8 billion, driven by the strong global demand for Wegovy®. Diabetes care maintained steady progress, with total GLP-1 therapies up 10% and Rybelsus® recording a 5% increase.
• Growth in Rare Disease Segment: The rare disease segment achieved sales of DKK 9.5 billion, up 15% year-over-year. Rare endocrine disorders grew 49%, supported by strong demand for Norditropin® and Sogroya®, while rare blood disorders rose 6%, led by NovoSeven® and Alhemo®.
• Broad-Based Geographic Growth: Novo Nordisk’s performance was geographically diversified, with balanced contributions across regions. The U.S. drove 54% of total growth, with sales increasing 17% to DKK 87.3 billion. International Operations expanded 19% to DKK 67.7 billion, led by standout performance in APAC (+35%), alongside growth in China (+6%) and Emerging Markets (+22%).
• Advancement in Innovation and Pipeline: The company continued to make significant progress in its R&D pipeline during Q2 FY25. Notable milestones included the EMA’s positive opinion for Ozempic® in peripheral arterial disease, the launch of the CagriSema phase 3b REDEFINE 11 trial, and the advancement of both oral and subcutaneous amycretin to phase 3. Furthermore, Alhemo® received U.S. approval, strengthening the company’s rare disease offerings.
• Commitment to Sustainability and Inclusion: Novo Nordisk made tangible progress in its sustainability and social initiatives, expanding access to treatment for 42.8 million people with diabetes and 2.9 million with obesity worldwide. Additionally, female representation in senior leadership increased to 43%, reflecting the company’s focus on inclusive growth and responsible corporate practices.

Technical Observation (on the daily chart):

Novo Nordisk A/S shares remain in a firm downtrend, trading at USD 48.53, below both the 20-day (USD 55.01) and 50-day (USD 56.16) moving averages, confirming sustained bearish momentum. The RSI at 12.0 indicates deeply oversold conditions, hinting at a possible short-term rebound, though the broader trend remains weak. Elevated volume (3.84M) reflects continued selling pressure.

Novo Nordisk delivered a strong first-half performance in FY25, underscored by double-digit growth in revenue, profitability, and shareholder returns. Sales rose 18% at constant exchange rates to DKK 154.9 billion, driven by exceptional momentum in obesity care, robust diabetes treatment demand, and solid expansion in rare diseases. Operating profit increased 29%, supported by improved efficiency and a higher-margin product mix, while free cash flow and shareholder distributions remained strong. Broad-based geographic growth, particularly in the U.S. and APAC, along with continued pipeline advancement and sustainability achievements, reinforced Novo Nordisk’s position as a global leader in healthcare innovation and responsible growth.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Buy’ rating has been given to Novo Nordisk A/S (NYSE: NVO) at the current market price of USD 48.53 as of Oct 31,2025 at 7:15 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is October 31,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.